Welcome to our dedicated page for Axsome Therapeut SEC filings (Ticker: AXSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Axsome Therapeutics, Inc. (NASDAQ: AXSM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer focused on central nervous system (CNS) conditions, Axsome uses its SEC reports to communicate financial results, product revenue for AUVELITY, SUNOSI, and SYMBRAVO, and updates on its development pipeline, which includes programs such as AXS-05, AXS-12, AXS-14, solriamfetol in new indications, and AZD7325.
Among the filings, Form 8-K current reports are especially relevant for tracking material events. For example, Axsome has filed 8-Ks to furnish press releases announcing quarterly financial results and to disclose updates such as the receipt of a Paragraph IV Certification Notice Letter regarding a proposed generic version of SYMBRAVO. These documents help investors understand how clinical progress, intellectual property developments, and commercial performance affect the company.
In addition to 8-Ks, investors typically review Axsome’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain detailed discussions of net product revenue, research and development spending, selling and administrative expenses, risk factors, and descriptions of the company’s CNS portfolio and pipeline. Proxy statements and, when applicable, Forms 3, 4, and 5 can provide information on insider holdings and transactions, while registration statements and prospectuses outline capital-raising activities.
Stock Titan enhances these filings with AI-powered summaries that explain the key points of lengthy documents such as 10-Ks, 10-Qs, and major 8-Ks in plain language. Real-time EDGAR updates help ensure that new Axsome filings appear promptly, and AI-generated highlights can make it easier to locate information on topics such as AXS-05’s regulatory status, AXS-12’s Orphan Drug Designation, or revenue trends for AUVELITY, SUNOSI, and SYMBRAVO without reading every page of the underlying filing.
Axsome Therapeutics is asking stockholders to vote at its 2026 Annual Meeting, a fully virtual event scheduled for June 5, 2026 at 9:00 a.m. EDT. Holders of common stock at the close of business on April 14, 2026, when 51,439,952 shares were outstanding, may attend online, submit questions, and vote.
Stockholders will elect two Class II directors to terms ending in 2029, ratify Deloitte & Touche LLP as independent auditor for 2026, and cast a non-binding advisory vote on named executive officer compensation. The board unanimously recommends voting “FOR” all three proposals. The proxy statement also details board composition, diversity data, executive and director pay, committee structures, and Axsome’s ESG and governance practices.
Jacobson Mark L. reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics, Inc. reported that Chief Operating Officer Mark L. Jacobson received a grant of 8,669 Performance Stock Units (PSUs). Each PSU represents a contingent right to receive one share of Axsome common stock.
The PSUs will vest only if specified sales and commercial launch milestones are achieved and if Jacobson remains in service through each vesting date. Following this grant, he holds 8,669 PSUs directly as part of his equity-based compensation.
TABUTEAU HERRIOT reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics, Inc. disclosed that Chief Executive Officer Herriot Tabuteau received a grant of 24,081 Performance Stock Units (PSUs) tied to the company’s common stock. Each PSU represents a contingent right to receive one share of common stock if specific sales and commercial launch milestones are achieved.
The PSUs will vest only upon meeting these milestones and require the CEO’s continued service on each vesting date. Following this grant, the reported holding for this PSU award is 24,081 units, reflecting a compensation-related equity incentive rather than an open-market share purchase or sale.
Axsome Therapeutics’ Chief Commercial Officer Ari Maizel reported an exercise-and-sell transaction involving 7,500 shares of common stock. He exercised stock options to acquire 7,500 shares at $70.73 per share, then sold the same 7,500 shares in open-market trades at a weighted average price of $182.42 per share.
The filing notes these sales were made under a pre-approved Rule 10b5-1 trading plan, indicating they were pre-scheduled rather than timed discretionarily. Following the transactions, Maizel reported no directly held common shares and 23,710 stock options (right to buy) remaining outstanding.
Maizel Ari reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics, Inc. reported that Chief Commercial Officer Ari Maizel received a grant of 7,224 Performance Stock Units (PSUs). Each PSU represents a contingent right to one share of common stock.
The PSUs vest only if specified sales and commercial launch milestones are achieved and if Maizel remains in service on each vesting date, making this a performance-based, at-risk equity award rather than an immediate share issuance.
Pizzie Nick reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics, Inc. reported that its Chief Financial Officer, Nick Pizzie, received a grant of 8,188 Performance Stock Units (PSUs). Each PSU represents a contingent right to receive one share of Axsome common stock.
The PSUs will vest only if certain sales and commercial launch milestones are achieved and if Pizzie continues in service on each vesting date. Following this award, he holds 8,188 PSUs tied to Axsome common stock.
Murdock Hunter R. reported acquisition or exercise transactions in this Form 4 filing.
Axsome Therapeutics, Inc. reported that its General Counsel, Hunter R. Murdock, received a grant of 7,224 Performance Stock Units (PSUs). Each PSU represents a contingent right to receive one share of Axsome common stock. The PSUs will vest only if specified sales and commercial launch milestones are achieved and if the executive continues in service through each vesting date. Following this award, Murdock holds 7,224 PSUs directly.
Axsome Therapeutics entered into an asset purchase agreement with Takeda to obtain exclusive global commercial, development, and manufacturing rights to balipodect (TAK-063), a novel, oral, selective PDE10A inhibitor. Axsome plans to develop balipodect for schizophrenia and Tourette syndrome and to start Phase 3 trial-enabling activities for schizophrenia in 2026.
Balipodect has completed a 164-patient proof-of-concept Phase 2 trial in schizophrenia and has shown a favorable safety and tolerability profile in clinical studies in over 360 individuals. Takeda received an upfront payment and may receive additional development, regulatory, and commercial milestone payments, plus royalties on potential global net sales.